Introduction
Dietary supplements (DS) are widely used as alternatives to traditional medical therapies. In most countries DS are not regulated as extensively as drugs and definitive evidence regarding their efficacy and safety, including results of pre-clinical animal safety testing and adverse event (AE) reports, is not always available (Bagchi, 2014; Devala et al., 2011; IOM, 2005; Marcus and Grollman, 2012) . Serious adverse health events resulting from DS use must be reported by DS manufacturers to the U.S. Food and Drug Administration (FDA) but for non-serious AE, manufacturers are only required to keep records for six months and there is no formal requirement to report minor adverse health events (Clauson et al., 2008; deBoer and Sherker, 2017; FDA, 2013; Pawar and Grundel, 2016) . The FDA did recently announce it will begin posting AE report data associated with foods, DS and cosmetics on the internet (DHHS, 2016) . It is estimated that less than 1 in 100 AE that occur are reported to regulatory authorities, and reports that are filed are difficult to aggregate and evaluate (Walji et al., 2009; Woo, 2007) . Scientists and regulatory officials from a number of countries, including the U.S. National Academy of Sciences, have called for improvements in the methods used for ensuring the safety of DS and detection of AE from consumption of DS (Borg et al., 2011; Gardiner et al., 2008; IOM, 2005; USGAO, 2009; Walji et al., 2009) .
The tree Ginkgo biloba L. has been cultivated in China for several thousand years and extracts of the leaves are used as dietary supplements (Stromgaard et al., 2010) . The most common therapeutic effects attributed to ginkgo extract are improved blood circulation and brain function, resulting in various cognitive benefits including memory enhancement in healthy individuals and those suffering from various illnesses including Alzheimer's disease (DeKosky et al., 2008; Ihl, 2013; Mohanta et al., 2014; NCCIH, 2016; Solomon et al., 2002; Stromgaard et al., 2010) , claims that are not supported by the literature (Popa, 2002) . In Germany and China, countries where herbal DS are particularly popular, ginkgo extract is the most commonly prescribed herbal supplement (Popa, 2002) . Ginkgo extract is also a popular herbal supplement in the U.S. and it is estimated that in 2007, 11.3% of Americans using non-vitamin, nonmineral supplements were using it (Barnes et al., 2008; Diamond and Bailey, 2013; Kleijnen and Knipschild, 1992) . Herbal supplements are particularly popular in the U.S. among certain groups of individuals such as those with various illnesses and college students (Farina et al., 2014; Lieberman et al., 2015) .
Supplements containing ginkgo extracts are widely believed to be safe and to only cause minor side effects such as stomach upset, headache, dizziness, constipation, and allergic skin reactions (NCCIH, 2016; Stromgaard et al., 2010) . However, several animal studies have reported toxic effects (Koch et al., 2013; Rider et al., 2014) including a large animal study using standardized toxicology testing methods that reported high doses of an extract of ginkgo biloba leaves increased risk of liver and thyroid cancer in mice and rats (NTP, 2013) . Few human studies have examined the adverse effects of commercially-available DS containing Ginkgo biloba, and the sample size of these trials in aggregate is modest compared to the sample size of clinical trials typically required for approval of prescription drugs (Carlson et al., 2007; Dodge et al., 2008; Gavrilova et al., 2014; Ihl et al., 2011; Kellermann and Kloft, 2011; Koehler et al., 2004; Le Bars and Kastelan, 2000; Le Bars et al., 1997; Pittler and Ernst, 2004) .
The National Health and Nutrition Examination Survey (NHANES) is designed to monitor the health and nutritional status of the U.S. population. The survey examines a nationally representative sample of approximately 5000 adults every year and includes an in-home survey and a mobile laboratory physical examination. Using standardized, state-of-the-art techniques, NHANES assesses food consumption and dietary supplement use, multiple measures of blood chemistry, body composition, cardiovascular fitness and numerous other health-related parameters of volunteers. Data from these surveys are used to determine prevalence of diseases and their risk factors, assess nutritional status and its association with health promotion and disease prevention, and assist with formulation of national standards and public health policy (CDC, 2016) . Because NHANES surveys are conducted using the same standardized procedures, very large data sets can be assembled by combining multiple years of data. By combining multiple years of NHANES a large number of reported DS consumers can be studied to determine if there is evidence of specific AE associated with use of a particular DS.
The primary objective of this study was, using NHANES 2001e2012 data, to determine if there is an association of consumption of commercial preparations containing extracts of Ginkgo biloba with alterations in clinical markers of liver function in U.S.
adults. In addition, as a positive control it was determined if the method used could detect changes in markers of liver function associated with alcohol intake, which is known to have adverse effects on the liver in high doses. It was hypothesized consumption of ginkgo preparations typical of those consumed by the U.S. population could alter these markers of liver function since recent animal toxicological studies have reported ginkgo extract intake has toxic effects on the liver (NTP, 2013; Rider et al., 2014) .
Methods

Study population
NHANES data are collected on a nationally representative sample of non-institutionalized Americans by the National Center for Health Statistics (NCHS) of the Center for Disease Control and Prevention (CDC), and released every two years (CDC, 2016) . All participants or proxies provided written informed consent and the Research Ethics Review Board at the NCHS approved the survey protocol. Data from NHANES 2001e2002, 2003e2004, 2005e2006, 2007e2008, 2009e2010 and 2011e2012 were combined for these analyses. The combined sample included 29,684 adults (age 19 years and older) excluding pregnant or lactating females. Participants completed an in-person health examination in a Mobile Examination Center that included a 24-h dietary recall and provided blood and urine specimens for laboratory analyses. Detailed description of the survey design and the data collection procedures are available elsewhere (CDC, 2016).
Estimates of ginkgo and alcohol intake
In conducting the NHANES 2001e2012, a dietary supplement questionnaire was administered in person during the household interview to assess use of vitamins, minerals, botanicals, and other dietary supplements over the past 30 days (CDC, 2016) . The interviewer also examined each dietary supplement container and recorded complete product information so that every reported dietary supplement could be matched or entered into a dietary supplements database. The NCHS maintains an extensive dietary supplement database that contains product label information including the labeled dosage or serving size, ingredients, and the amounts of ingredients per serving (CDC, 2016) . Ginkgo intake in milligrams from each ginkgo-containing commercial preparation used was calculated from the NHANES dietary supplement intake files that contained 42 different dietary supplement codes (different manufacturer forms and concentration levels) and ginkgo consumers were defined as those consuming any amount of a ginkgo preparation over the past 30 days. A complete list and a detailed description of these preparations can be derived using the public NHANES data files associated with each 2-year cycle examined that are available on the CDC website (CDC, 2016) . Alcohol intake was calculated as average number of drinks (12 oz of beer, 5 oz of wine and/or 1.5 oz of liquor) per day over the last year using the NHANES 2001e2012 alcohol questionnaire and alcohol consumers were defined as those consuming any amount of alcohol (CDC, 2016).
Outcome variables for markers of liver function
Laboratory test values for the following liver enzymes in blood samples from NHANES 2001e2012 were compared across consumers and non-consumers of ginkgo or alcohol: alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH) and bilirubin levels. The activities of ALP, ALT, AST, GGT and LDH were measured spectrophotometerically using their respective kinetic enzymatic methods and bilirubin levels were measured spectrophotometerically using a timed-endpoint diazo method (CDC, 2016) . ALT and AST are aminotransferases that, when elevated, are indicative of reduced hepatocyte integrity. GGT is a marker of cholestasis and LDH is a marker of ischemic liver damage (CDC, 2016; Limdi and Hyde, 2003; Woreta and Alqahtani, 2014) . LDH is also a marker of heart disease and lung or kidney tumors (CDC, 2016) . Bilirubin is used as a marker of liver function as hepatobiliary diseases will affect its uptake, storage and excretion (CDC, 2016; Limdi and Hyde, 2003; Woreta and Alqahtani, 2014) .
Statistical analysis
Analyses were conducted using SAS 9.2 (SAS Institute, Inc.; Cary, NC) and SUDAAN release 11.0 (Research Triangle Institute; Research Triangle Park, NC). Appropriate weighting factors were used to adjust for oversampling of selected groups, survey non-response of some individuals, and day of the week when the interview was conducted. Least square means and standard errors (SE) of laboratory parameters were determined using PROC REGRESS of SUDAAN after adjustment for various covariates. Outcome variables were adjusted for gender, race-ethnicity, age, physical activity (categorized as sedentary, moderate, or vigorous based on responses to questions on activity), poverty income ratio, smoking habits (yes/no), energy intake and BMI. In a separate set of regression analyses, alcohol intake was added as an additional covariate to those described above and we assessed whether there was an interaction of ginkgo consumption and alcohol intake. Differences in least square means of consumers and non-consumers were determined. Significance was set at P < 0.01.
Results
Alcohol
Approximately 65.7% of NHANES 2001e2012 adult participants were alcohol consumers with a mean intake of 0.80 ± 0.02 drinks/ day (Agarwal et al., 2016) . Mean male intake was more than double that of the females (Table 1) . Alcohol consumers were more likely to be younger, non-Hispanic white, smokers, physically active and have higher income, and less likely to be females, non-Hispanic black, and have a sedentary life style (Table 1) .
Alcohol consumers (gender combined) compared to nonconsumers, had significantly lower ALP (4.3%, P < 0.0001), and higher AST (4.8%, P < 0.0001) and GGT (20.6%, P < 0.0001) ( Table 2) . No significant difference among consumers and non-consumers was noted for the activity of ALT (P ¼ 0.0460) and LDH (P ¼ 0.4914). Activities of AST and GGT were higher in both male (AST 5.6%, P ¼ 0.0009; GGT 24.6%, P < 0.0001) and female (AST 4.8%, P ¼ 0.0003; GGT 16.2%, P < 0.0001) consumers compared to nonconsumers. Activities of ALT were significantly higher only in male consumers compared to male non-consumers (6.6%, P ¼ 0.0015) but not in female consumers (who consumed less alcohol on average than males) compared to female nonconsumers (P ¼ 0.9273). Activities of ALP were significantly lower in both male (3.3%, P ¼ 0.0018) and female (4.0%, P < 0.0001) consumers compared to non-consumers (Table 2 ). Bilirubin levels were also higher in female alcohol consumers compared to nonconsumers of alcohol (3.0%, P ¼ 0.0012) but not in males (P ¼ 0.9227) or in gender-combined analyses (P ¼ 0.1849).
Ginkgo biloba preparations
Approximately 2.51% of NHANES 2001e2012 adult participants were ginkgo consumers (N ¼ 616); their mean intake of ginkgo preparations was 65.1 ± 4.4 mg/day. Since NHANES is a nationally representative sample of the U.S. adult population this indicates that over the time period examined more than 5 million adults were taking Ginkgo biloba preparations. There was considerable variation in the labeled doses of the Ginkgo biloba preparations consumed (4e720 mg/serving); the most common dose was 60 mg/serving (44% of consumers). Median intake (50 th percentile intake) of ginkgo among adult ginkgo consumers was 48.0 ± 6.6 mg/day (41.2 ± 7.2 mg/day for males; 47.0 ± 6.6 mg/day for females). Consumers of ginkgo preparations were more likely to be older, non-Hispanic white and have higher income, and less likely to be Mexican American, non-Hispanic black or have a sedentary lifestyle compared to non-consumers (Table 3 ). The activities of liver enzymes and bilirubin levels of ginkgo preparation consumers and non-consumers are presented in Table 4 . The difference in liver enzymes and bilirubin levels of ginkgo consumers and non-consumers was not statistically significant (P > 0.01). In addition, no significant differences (P > 0.01) in liver enzymes and bilirubin levels between consumers and nonconsumers were observed when the data were stratified by gender (Table 4) . When subjects with liver disease (19 ginkgo consumers and 988 non-consumers) were excluded, or when alcohol intake was used as covariate there were still no significant differences in liver enzymes and bilirubin levels between consumers and non-consumers (data not shown). Additionally there were no significant interactions between ginkgo and alcohol intake for activities of liver enzymes or bilirubin levels (data not shown).
To determine whether there were dose-related differences in liver enzymes and bilirubin levels in ginkgo preparation consumers, we compared high and low ginkgo consumers with nonconsumers by stratifying users into two groups with intakes that were either higher (high ginkgo consumers) or lower than the median intake level of 48.0 ± 6.6 mg/day (low ginkgo consumers). Activities of liver enzymes (ALP, ALT, AST, GGT & LDH) and bilirubin levels for high ginkgo consumers and low ginkgo consumers did not differ from those of non-consumers in male and female adults, analyzed individually as well as when genders were combined (P > 0.01). In addition, no significant trends (P > 0.01) were noted for ALP, ALT, AST, GGT or LDH activities or bilirubin levels across non-consumers, low ginkgo consumers and high ginkgo consumers (Table 5) . Additionally, there were no significant dose-related differences or trends when subjects with liver disease (19 ginkgo consumers and 988 non-consumers) were excluded or when alcohol intake was used as covariate (data not shown).
Discussion
Alcohol
Excessive alcohol consumption can cause liver diseases including fatty liver, hepatitis and cirrhosis and liver cancer (O'Shea et al., 2010; Schwartz and Reinus, 2012) . We compared liver enzyme concentrations between alcohol consumers and nonconsumers as a positive control to determine whether the analytical approach used in this study would be sensitive to small changes in liver function well within standard laboratory reference intervals. Significantly higher AST and GGT concentrations were present in alcohol consumers compared to non-consumers but did not approach levels that would be considered clinically abnormal and are an indication of the sensitivity of the approach used. Serum GGT, the most sensitive measure of alcohol consumption in this study with regard to the magnitude of the difference between alcohol consumers and non-consumers, is considered to be the most sensitive indicator of liver disease (Mayo Clinic, 2014) . Significantly lower levels of ALP were observed among male and female alcohol consumers. In a previous study we observed a curvilinear dose-effect relationship (inverse U-shaped) between amount of alcohol intake and ALP activity. At lower doses of alcohol an inverse linear component was present indicating a decrease in ALP with low to moderate alcohol intake and, at higher doses, a positive curvilinear component indicating that, as alcohol intake increased further, ALP increased (Agarwal et al., 2016) . Previous studies have reported induction of liver enzyme function with excessive alcohol consumption (Alatalo et al., 2009; Conigrave et al., 2003; Hietala et al., 2005; Tsai et al., 2012) , and a few studies also reported altered liver enzyme activities with moderate alcohol intake (Agarwal et al., 2016; Alatalo et al., 2009; Hietala et al., 2005) . Our findings indicate metabolic markers may be used to examine the effects of dietary components in a freeliving population prior to onset of clinically diagnosable dysfunction or presence of significant side-effects.
Ginkgo biloba preparations
Adults consuming ginkgo preparations had similar liver enzyme levels of ALP, ALT, AST, GGT, LDH and bilirubin levels as those not consuming such products. Furthermore, dose-effect and regression analyses demonstrated there were no dose-related effects of ginkgo preparations on any of the markers of liver damage assessed. The liver is one of the primary organs responsible for metabolizing drugs and many dietary supplements, including ginkgo biloba (Bunchorntavakul and Reddy, 2013; Stickel et al., 2011) . Several herbal dietary supplements (e.g. black cohosh, chaparral, germander, greater celandine, kava, pennyroyal, etc.) have been reported to affect liver function and cause liver injury (Bunchorntavakul and Reddy, 2013; Heidemann et al., 2016; Navarro and Lucena, 2014) . Ginkgo is also reported to inhibit liver cytochrome P450 activity in in-vitro systems (NIH, 2016; von Moltke et al., 2004; Zadoyan et al., 2012) . Levels of ALP, ALT, AST, GGT and LDH are biological markers associated with injury to the hepatic system and are assessed for diagnostic purposes and as part of routine physical examinations (Alatalo et al., 2009; Conigrave et al., 2003; Limdi and Hyde, 2003) . When the concentrations of these enzymes in the blood are abnormal they are strong predictors of morbidity and mortality associated with liver disease, cardiovascular disease, diabetes and cancer (Kim et al., 2004; Kunutsor et al., 2014; Targher, 2010) . Changes in their levels are excellent predictors of the subsequent development of hepatocellular cancer in humans (Stepien et al., 2016) .
Levels of another indicator of liver injury, bilirubin, were also similar in ginkgo consumers and non-consumers. This demonstrates that ginkgo preparation consumers who consume an average of 65.1 ± 4.4 mg of ginkgo/day do not have any indication of altered liver function when their markers of liver function are assessed and compared to the levels of non-consumers. It is however possible that ginkgo may have effects on other liver metabolic pathways, therefore these findings should not be interpreted as conclusively demonstrating ginkgo extract consumption does not have toxic effects on the human liver.
Adverse events and toxicity
At present, there is no standardized, systematic process for evaluating the risks and benefits of dietary supplements and in the U.S., and many other countries, manufacturers are responsible for ensuring DS safety (IOM, 2005) . The assessment of AE associated with DS offers unique challenges based on the quantity and quality of available information. In the U.S., the FDA is responsible for monitoring AE associated with DS consumption, and requires reporting of only serious AE and six months of recordkeeping of all non-serious AE (Clauson et al., 2008; deBoer and Sherker, 2017; FDA, 2013; Pawar and Grundel, 2016) . MedWatch is the FDA's agency-wide safety information and adverse event reporting program.
The Center for Food Safety and Applied Nutrition (CFSAN) also collects and stores AE reports related to foods and dietary supplements and DS manufacturers are required to provide the company's contact information on the product label for consumer reporting of AE (Pawar and Grundel, 2016) . Similar AE reporting systems are used in other countries, for example the "yellow card" scheme is used in the UK and the "blue card" is used in Australia to monitor safety (Shaw et al., 2012) . In the U.S., although manufacturers are required to keep records of all non-serious AE for six months there is no formal reporting requirement for minor AE (Clauson et al., 2008; deBoer and Sherker, 2017; FDA, 2013; Pawar and Grundel, 2016) . Recently, the FDA announced that it will begin posting AE report data associated with foods, DS and cosmetics on the internet on a quarterly basis (DHHS, 2016) . It is estimated more than 99% of all AE are not reported and it has been noted that AEs that are reported are difficult to aggregate and evaluate (Walji et al., 2009; Woo, 2007) . AE associated with specific dietary supplements are difficult to evaluate, and most studies examining the AE of dietary supplements have not been well-controlled clinical trials (Pittler and Ernst, 2004) . As part of a comprehensive review of DS safety, the National Academy of Sciences has concluded that multiple signals should be considered when safety of DS is monitored by the FDA (IOM, 2005) , and analysis of NHANES data may provide such information.
We did not find any systematic record of non-serious AEs in publically available databases such as FDA Adverse Event Reporting System (FDA, 2016), Canada Vigilance Adverse Reaction Online Database (Health Canada, 2016) , the Therapeutic Goods Administration Database of Adverse Event Notifications (TGA, 2013) or the World Health Organization (Vigibase) (Uppsala Monitoring Centre, 2016) for ginkgo extracts. However, a few recent reviews have compiled published data on adverse effects of plant/herbal supplements in humans, however, these only noted potential effects of ginkgo extracts on hemorrhagic outcomes (Di Lorenzo et al., 2014; Posadzki et al., 2013) .
Ginkgo extract DS are generally well-tolerated by humans (ESCOP, 2003; Fransen et al., 2010; NCCIH, 2016; Stromgaard et al., 2010) , however some mild side effects, such as gastrointestinal complaints, headache, allergic skin reactions, nausea, dizziness, restlessness, heart palpitation, weakness, and risk of bleeding have been reported (Di Lorenzo et al., 2014; Fransen et al., 2010; Kellermann and Kloft, 2011; Koehler et al., 2004; NCCIH, 2016; Pittler and Ernst, 2000; Stromgaard et al., 2010) . However, a meta-analysis of human studies did not find a higher bleeding risk due to consumption of ginkgo extract (Kellermann and Kloft, 2011) . Additionally, a large clinical trial of ginkgo for the prevention of dementia did not find any difference in serious AE between the ginkgo and placebo treatment groups (DeKosky et al., 2008) .
In the peer-reviewed published literature there are little or no human data on hepatic toxicity, reproductive toxicity, neurotoxicity or immune-toxicity of ginkgo extracts (Fransen et al., 2010; NTP, 2013; Stromgaard et al., 2010) . However, a recent U.S. National Toxicology Program (NTP) study (NTP, 2013) reported significant hepatic and thyroid toxicity (measured by necropsy, clinicalpathology and histopathology) in rats receiving daily ginkgo leaf extract doses of 62.5e1000 mg/kg and mice receiving 125e2000 mg/kg 5 days per week for 14 weeks. In addition, dosedependent increases in risk of cancers of liver and thyroid with ginkgo leaf extract (100e1000 mg/kg/day for rats, and 200e2000 mg/kg/day for mice) administered 5 days per week for 2 years were observed. The statistical approaches used in this study have been questioned (Gaus, 2014) and these challenges rebutted by others (Kissling et al., 2015) . The ginkgo leaf extract doses tested in the NTP study (NTP, 2013) were substantially higher than the current average intake of about 60 mg/day in the U.S. adult ginkgo consumers we studied. Additional safety studies exploring the adverse effects of ginkgo extract in a range of doses equivalent to current human intake are warranted. Such studies should include assessment of biochemical biomarkers of ginkgo intake and evaluate potential adverse interactions with common drugs.
Limitations and strengths
One limitation of our study is that the cross-sectional nature of NHANES is not designed to determine cause-effect relationships. Additionally there is the potential for bias in the use of selfreported intakes of alcohol and/or ginkgo (Stockwell et al., 2014) . Also the measurement of self-reported ginkgo intake was reliant on product label values provided by manufacturers and we could not obtain blood or urinary markers of ginkgo intake as these are not collected by NHANES. Furthermore, the ginkgo consumers studied used various forms of ginkgo extract, not a single standardized formulation or standard dose as would be used in a clinical trial. The quality and the formulation of ginkgo preparations used by the NHANES participants also could not be fully ascertained since manufacturers are not required to report complete details on the label. It should also be noted that although we included over 600 ginkgo extract consumers in our analysis, this sample size could be too small to detect a very low incidence of liver injury. A major strength of our study is the use of a large nationally representative population-based sample of adults. We are not aware of any study where such a large, representative sample of the U.S. population has been studied to determine whether the ginkgo biloba extracts commonly used in the US may cause AE.
Conclusions
The data presented in this study show moderate alcohol consumption alters many biomarkers of liver function, but the herbal dietary supplement ginkgo biloba, in the formulations and doses typically consumed by adult Americans, does not affect the same enzymes. The use of data from NHANES surveys, especially when combined over multiple years, provide an opportunity to study potential adverse effects of dietary supplements and other dietary constituents, especially supplements or food constituents potentially associated with changes in a wide variety of biomarkers assessed as part of NHANES.
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